Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5566-5575

  Manzoor, Ashley A ^a,c   Lindner, Lars H ^d,e,f   Landon, Chelsea D ^c   Park, Ji Young ^c   Simnick, Andrew J ^b   Dreher, Matthew R ^g   Das, Shiva ^a,c   Hanna, Gabi ^c   Park, Won ^c   Chilkoti, Ashutosh ^b   Koning, Gerben A ^d   Ten Hagen, Timo L M ^d   Needham, David ^b   Dewhirst, Mark W ^a,b,c  

^a Medical Physics Program   (United States)

^b Duke University   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG TUMOR LEVEL; HEAT SENSITIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOSOMAL DELIVERY; MELANOMA; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HOT TEMPERATURE; HUMANS; LIPOSOMES; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868256944     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1683     Document Type: Article

References (49)

1. Papahadjopoulos D. Liposomes and their uses in biology and med-icine. New York: New York Academy of Sciences; 1978.
2. Allen TM.Liposomal drug for mulations. Rationale for development and what we can expect forthe future. Drugs 1998;56:747-56.
3. Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 2005;13:73-80.
4. Kabanov AV, Batrakova EV, Alakhov VY. Pluronicblockco polymersas novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82:189-212.
5. Discher BM, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, et al. Polymersomes: tough vesicles made from diblock copolymers. Sci-ence 1999;284:1143-6.
6. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-6.
7. Maeda H, Sawa T, Konno T. Mechanism oftumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001;74:47-61.
8. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027-32.
9. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer G, van Tiel ST, et al. Tumor necrosis factor alpha mediateshomogeneousdistributionofliposomesinmurinemelanoma that contributes to a better tumor response. Cancer Res 2007;67: 9455-62.
10. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther2010;9:1798-808.
11. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and char-acterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
12. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumorvascular permeability, accumulation, and penetration of mac-romolecular drug carriers. J Natl Cancer Inst 2006;98:335-44.
13. El-Kareh AW, Secomb TW. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxo-rubicin to tumor cells. Neoplasia 2000;2:325-38.
14. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 2004;10:2168-78.
15. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Need-ham D, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000;60:6950-7.
16. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new tem-perature-sensitive liposome for use with mild hyperthermia: charac-terization and testing in a human tumorxenograft model. Cancer Res 2000;60:1197-201.
17. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53:285-305.
18. Hossann M, Wiggenhorn M, Schwerdt A, Wachholz K, Teichert N, Eibl H, et al. In vitro stability and content release properties of phosphatidylgly ceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 2007;1768:2491-9.
19. Lindner LH, Hossann M, Vogeser M, Teichert N, Wachholz K, Eibl H, et al. Dual role of hexadecylphosphocholine (miltefosine) in thermo-sensitive liposomes: active ingredient and mediator of drug release. J Control Release 2008;125:112-20.
20. Schlemmer M, Wendtner CM, Lindner L, Abdel-Rahman S, Hiddemann W, Issels RD. The rmochemo therapy in patients with extremity high-risk soft tissue sarcomas (HR-STS). Int J Hyperthermia 2010;26: 127-35.
21. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, et al. Comparative effects ofthermosensitive doxorubicin-containing iposomes and hyperthermia in human and murine tumours. Int J Hyperthermia 2010;26:485-98.
22. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, et al. Magnetic resonance imaging oftemperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007;99:53-63.
23. Weinstein JN, Magin RL, Yatvin MB, Zaharko DS. Liposomesandlocal hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979;204:188-91.
24. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of lipo-somes for enhanced local release of drugs by hyperthermia. Science 1978;202:1290-3.
25. Yatvin MB, Muhlensiepen H, Porschen W, Weinstein JN, Feinendegen LE. Selective delivery of liposome-associated cis-dichlorodiammine-platinum(II) by heat and its influence on tumordrug uptake and growth. Cancer Res 1981;41:1602-7.
26. Papenfuss HD, Gross JF, Intaglietta M, Treese FA. A transparent access chamber for the rat dorsal skin fold. Microvasc Res 1979; 18:311-8.
27. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 1985;816:294-302.
28. Li L, ten Hagen TL, Schipper D, Wijnberg TM, van Rhoon GC, Egger-mont AM, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release 2010;143:274-9.
29. Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 1981;5:267-70.
30. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother2009;10:333-43.
31. Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, vander Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999;5:1703-7.
32. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution oftheanticancerdrug doxorubicin in relation to bloodvessels in solid tumors. Clin Cancer Res 2005;11:8782-8.
33. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjo-poulos D. Thermosensitive liposomes: extravasation and release of contentsintumormicrovascularnetworks. Int J Radiat Oncol Biol Phys 1996;36:1177-87.
34. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-spe-cific nanoparticle delivery: effect of particle size. Cancer Res 2000;60: 4440-5.
35. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
36. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 over-expressing xenografts. Clin Cancer Res 2008;14:2171-9.
37. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007;13:2804-10.
38. Weinstein JN, Magin RL, Cysyk RL, Zaharko DS. Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate. Cancer Res 1980;40: 1388-95.
39. Hauck ML, La Rue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, et al. Phase I trial ofdoxorubicin-containing lowtemperaturesensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006;12: 4004-10.
40. Landon CD, Park JY, Needham D, Dewhirst MW. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in com-binationwith mild hyperthermiainthetreatment of local cancer. Open Nanomed J 2011;3:38-64.
41. Celsion. A study of Thermo Dox™ in combination with radiofrequency ablation (RFA) in primary and metastatic tumors of the liver [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 - [cited 2012 June 15]. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00441376 NLM Identifier: NCT00441376.
42. Celsion. Phase 3 study of Thermo Dox with radiofrequency ablation (RFA) in treatment of hepatocellular carcinoma (HCC) [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 - [cited 2012 June 15]. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00617981 NLM Identifier: NCT00617981.
43. Celsion. Phase 1/2 study of Thermo Doxwith approved hyperthermia in treatment of breast cancer recurrence at the chest wall (DIGNITY) [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 -[cited 2012 June 15].Availablefrom: http://www.clinicaltrials.gov/ct2/ show/NCT00826085 NLM Identifier: NCT0826085.
44. Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, et al. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol 1997;24: 616-25.
45. van der Zee J, Vujaskovic Z, Kondo M, Sugahara T. The Kadota Fund International Forum 2004-clinical group consensus. Int J Hyperther-mia 2008;24:111-22.
46. Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone orwith regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multi-centrestudy. Lancet Oncol 2010;11:561-70.
47. Cardenas-Navia LI, Secomb TW, Dewhirst MW. Effects offluctuating oxygenation on tirapazamine efficacy: theoretical predictions. Int J Radiat Oncol Biol Phys 2007;67:581-6.
48. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancerdrugs. J Natl Cancer Inst 2006;98:1118-28.
49. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 2001;61:2907-10.